Search PubMed⌕ Search

Biomedical subjects

H Blomgren

Publications and source records attributed to H Blomgren.

At least 127 records · Page 7Linked to original sources
PubMed1980

Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls.

IgG fractions from serum of patients with transitional-cell carcinoma of the urinary bladder (TCC), patients with carcinoma of the prostate (CC) and healthy donors (HD) were tested for their capacity to induce antibody-dependent lymphocyte-mediated cytotoxicity (ADCC) to tumor cells in vitro. Lymphocytes from healthy donors were selected for low natural cytotoxicity to the target cells from established cell lines of TCC or other origins. IgG was prepared by adsorption of serum to Sepharose-bound protein A from Staphylococcus aureus and subsequent acid elution. When tested against a panel of six different target cells, most individual IgG preparations from all three donor groups contained antibodies inducing ADCC to some of the target cells. When IgG preparations from II untreated TCC patients were studied for ADCC induction to the TCC target T24 and the colon carcinoma HT29, cytotoxicity to T24 was, on an average, significantly higher than that to HT29. For IgG preparations from 18 TCC patients, treated with radiotherapy, a similar difference was seen but was not statistically significant. IgG preparations from II patients with carcinoma of the prostate and from 12 healthy donors did not show this differences. Moreover, while individual IgG preparations from untreated TCC patients were, on the average, significantly more cytotoxic to T24 than those from either of the two control groups, no such differences were seen when HT29 was the target. On the contrary, IgG preparations from patients with prostatic carcinoma were significantly more cytotoxic to HT29 than those from healthy donors. The results suggest that TCC patients develop a disease-related humoral immune response, superimposed on a "natural" immunity to a variety of antigens on the target cells used. The nature of the antigens involved in these reactions remains to be established. However, the results are compatible with previous findings, in these patients, of a bladder-tumor-related cellular cytotoxicity, to a large extent caused by the patients' own antibodies.

Aged↗
PubMed1980

Bestatin treatment and the peripheral lymphocyte population in cancer patients.

Bestatin, a substance produced by Streptomyces olivoreticuli, inhibits certain cell-membrane-associated enzymes and has been shown to augment immune responses in experimental animals. We have determined whether bestatin medication changed the peripheral lymphocyte population in 15 advanced cancer patients. After 2 weeks of daily, 30 mg oral bestatin medication, the lymphocyte counts remained essentially unchanged, but the frequency of E-rosette-forming lymphocytes increased. In vitro stimulation of the lymphocytes with PHA or PPD remained essentially unchanged while the natural-killer activity of the lymphocyte population increased in most patients. Bestatin treatment caused no detectable side effects.

Adjuvants, Immunologic↗
PubMed1980

Proliferation of C3H x CBA hybrid lymphocytes in the spleens of irradiated CBA mice: inhibition of this phenomenon by pretreatment of the hosts with C3H x CBA spleen cells.

Lymphocytes from C3H x CBA hybrid mice proliferate intensely in the spleens of irradiated CBA mice. Pretreatment of the CBA hosts with C3H x CBA spleen cells, known to specifically reduce the T-cell reactivity of the hosts against the strongly stimulatory Mls-antigen determined by the C3H-genome, abolished the capacity of the host to promote proliferation of C3H x CBA lymphocytes. In contrast, proliferation of C3H x CBA bone marrow cells, as measured by splenic 59Fe incorporation, was unaffected by such pretreatment. By examining the capacity of spleen cell populations of (C3H x CBA) x CBA back-cross mice to inhibit lymphocyte proliferation, as described above, and to express the C3H-determined Mls-antigen, it was concluded that these two traits are associated.

Animals↗
PubMed1980

Enhancement of the human mixed lymphocyte culture response by pretreating the stimulating cells with interferon.

The influence of interferon (IF) on the human mixed lymphocyte culture (MLC) reaction was examined. The presence of human IF in the MLCs but not pretreatment of the responding cell population with IF reduced the reaction. Pretreatment of the stimulating cells with human IF enhanced their MLC stimulatory capacities. This effect was observed with four different IF preparations of varying origin and purity, but not with a human mock or a mouse IF preparation.

Animals↗
PubMed1980

Effect of an intramuscular injection of human leukocyte interferon on blood leukocyte counts and proportions of lymphocytes forming E, EA and EAC rosettes.

Following an intramuscular injection of human leukocyte interferon blood leukocyte counts decreased in most patients as tested 24 h after the injection. This decrease comprised lymphocytes, monocytes and granulocytes, 24 h after interferon injection, the proportion of lymphocytes forming E rosettes was incresed in most patients, whereas the proportion of lymphocytes forming EA and EAC rosettes was not significantly changed.

Adolescent↗
PubMed1980

Natural killer activity in peripheral lymphocyte population following local radiation therapy.

The natural killer (NK) activity of peripheral lymphocytes against 51Cr-labelled Chang or K562 cells was tested using a 4 h release assay before and after postoperative radiation therapy for mammary carcinoma. NK activity against K562 was significantly reduced at completion of therapy (a total target dose of 45.0 Gy) and restituted 3 to 4 months later. NK activity against Change cells exhibited a slight but non-significant decline at completion of therapy followed by an overshoot 3 to 4 months later. The frequency of Fc-IgG receptor bearing lymphocytes was decreased at completion of therapy and largely restored after 3 to 4 months.

Adult↗
PubMed1980

Suppressor T cells in mycosis fungoides and so-called premycotic eruptions.

The proportions of suppressor T cells (TG) and helper T cells (TM) were determined in 5 patients with Mycosis fungoides (MF), 4 patients with parapsoriasis en plaques/poikiloderma atrophicans vasculare and 3 patients with generalized chronic dermatitis. All the MF patients showed increased proportions of suppressor T cells, whereas the others did not differ from age- and sex-matched healthy controls.

Adult↗
PubMed1980

Influence of bleomycin and pepleomycin on mitogen stimulations of human lymphocytes in vitro.

Bleomycin (BLM) and Pepleomycin (PEP), two antineoplastic drugs, strongly inhibited PHA-triggered DNA-synthesis of human lymphocytes when present during the culture period. Preincubation of lymphocytes with BLM or PEP for 3 days, however, only reduced the subsequent PHA-stimulations at very high drug concentrations. This differential sensitivity of resting and activated lymphocytes made it possible to inactivate subsets of mitogen or MLC reactive lymphocytes with a high grade of selectivity.

Adult↗
PubMed1980

Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.

Twenty one patients with advanced metastatic cancer of various types received 30 mg of Bestatin daily per os as a single treatment for several weeks. It was observed that the blood lymphocyte counts remained unchanged but the frequency of SRBC rosette forming cells increased and the frequency of lymphocytes possessing receptors for the Fc-part of IgG became normalized after two weeks of treatment. The frequency of lymphocytes possessing receptors for C'3 was not changed. The natural killer activity of peripheral lymphocytes for K562 and Chang cells increased but the PPD stimulation of the lymphocytes was not altered. A slight, but significant increase of the PHA stimulation of lymphocytes was observed after 4-7 weeks of Bestatin treatment. It is concluded that Bestatin is a nontoxic drug which changes the cellular composition as well as certain immunological functions of human lymphocytes.

Adult↗
PubMed1979

The effect of in vitro irradiation on mitogenic responsiveness of peripheral blood lymphocytes from untreated patients with Hodgkin's disease.

Peripheral blood lymphocytes from six untreated patients with Hodgkin's disease were exposed to various doses of ionizing radiation in vitro and thereafter tested for reactivity to PHA and ConA using DNA synthesis as a marker of viability. While the responsiveness of Hodgkin's disease lymphocytes was abolished by moderate radiation doses, the proliferative activity of healthy controls' lymphocytes was reduced in a biphasic fashion suggesting the presence of one relatively radiation-sensitive and one relatively resistant cell population.

Adult↗